Germany's new early benefit assessment for innovative pharmaceuticals
This article was originally published in SRA
Executive Summary
Jörg Schickert and Andreas Schmitz bring clarity to some of the pressing questions surrounding the new system of assessment that replaced free drug pricing. There is confusion over the scope of the assessment, dossier obligations and the determination of the comparable therapy.